This title appears in the Scientific Report :
2022
Please use the identifier:
http://dx.doi.org/10.2967/jnumed.121.262290 in citations.
Please use the identifier: http://hdl.handle.net/2128/32636 in citations.
An 89Zr-Labeled PSMA Tracer for PET/CT Imaging of Prostate Cancer Patients
An 89Zr-Labeled PSMA Tracer for PET/CT Imaging of Prostate Cancer Patients
The short half-life of existing prostate-specificmembraneantigen (PSMA) tracers limits their time for internalization into tumor cells after injection, which is an essential prerequisite for robust detection of tumor lesions with low PSMA expression on PET/CT scans. Because of its longer half-life,...
Saved in:
Personal Name(s): | Dietlein, Felix |
---|---|
Kobe, Carsten / Vázquez, Sergio Muñoz / Fischer, Thomas / Endepols, Heike / Hohberg, Melanie / Reifegerst, Manuel / Neumaier, Bernd / Schomäcker, Klaus / Drzezga, Alexander E. / Dietlein, Markus (Corresponding author) | |
Contributing Institute: |
Molekulare Organisation des Gehirns; INM-2 Nuklearchemie; INM-5 |
Published in: | Journal of nuclear medicine, 63 (2022) 4, S. 573 - 583 |
Imprint: |
New York, NY
Soc.
2022
|
DOI: |
10.2967/jnumed.121.262290 |
Document Type: |
Journal Article |
Research Program: |
Neuroimaging |
Link: |
OpenAccess |
Publikationsportal JuSER |
Please use the identifier: http://hdl.handle.net/2128/32636 in citations.
LEADER | 07457nam a2200937 a 4500 | ||
---|---|---|---|
001 | 910154 | ||
005 | 20230123110657.0 | ||
024 | 7 | |a 10.2967/jnumed.121.262290 |2 doi | |
024 | 7 | |a 0022-3123 |2 ISSN | |
024 | 7 | |a 0097-9058 |2 ISSN | |
024 | 7 | |a 0161-5505 |2 ISSN | |
024 | 7 | |a 1535-5667 |2 ISSN | |
024 | 7 | |a 2159-662X |2 ISSN | |
024 | 7 | |a 2128/32636 |2 Handle | |
024 | 7 | |a 34326129 |2 pmid | |
024 | 7 | |a WOS:000796182700014 |2 WOS | |
037 | |a FZJ-2022-03641 | ||
082 | |a 610 | ||
100 | 1 | |a Dietlein, Felix |0 P:(DE-HGF)0 |b 0 | |
245 | |a An 89Zr-Labeled PSMA Tracer for PET/CT Imaging of Prostate Cancer Patients | ||
260 | |a New York, NY |c 2022 |b Soc. | ||
520 | |a The short half-life of existing prostate-specificmembraneantigen (PSMA) tracers limits their time for internalization into tumor cells after injection, which is an essential prerequisite for robust detection of tumor lesions with low PSMA expression on PET/CT scans. Because of its longer half-life, the 89Zr-labeled ligand 89Zr-PSMA-DFO allows acquisition of PET scans up to 6 d after injection, thereby overcoming the above limitation. We investigated whether 89Zr-PSMA-DFO allowed more sensitive detection of weak PSMA-positive prostate cancer lesions. Methods: We selected 14 prostate cancer patients with biochemical recurrence who exhibited no PSMA-positive lesions on a PET scan acquired with existing PSMA tracers (68Ga-PSMA-11, 18F-JK-PSMA-7). Within 5 wk after the negative scan result, we obtained a second PSMA PET scan using 89Zr-PSMA-DFO (117 6 16 MBq, PET acquisition within 6 d of injection). Results: 89Zr-PSMADFO detected 15 PSMA-positive lesions in 8 of 14 patients, who had a PET-negative reading of their initial PET scans with existing tracers. In these 8 patients, the new scans revealed localized recurrence of disease (3/8), metastases in lymph nodes (3/8), or lesions at distant sites (2/8). On the basis of these results, patients received lesiontargeted radiotherapies (5/8), androgen deprivation therapies (2/8), or no therapy (1/8). The plausibility of 14 of 15 lesions was supported by histology, clinical follow-up after radiotherapy, or subsequent imaging. Furthermore, comparison of the 15 89Zr-PSMA-DFO–positive lesions with their correlates on the original PET scan revealed that established tracers exhibited mild accumulation in 7 of 15 lesions; however, contrast-to-noise ratios were too low for robust detection of these lesions (contrast-to-noise ratios, 2.4 6 3.7 for established tracers vs. 10.2 6 8.5 for89Zr-PSMA-DFO, P 5 0.0014). The SUVmax of the 15 89ZrPSMA-DFO–positive lesions (11.5 6 5.8) was significantly higher than the SUVmax on the original PET scans (4.7 6 2.8, P5 0.0001). Kidneys were the most exposed organ, with doses of 3.3 6 0.7 mGy/MBq. The effective dose was 0.15 6 0.04 mSv/MBq. Conclusion: In patients with weak PSMA expression, a longer period of time might be needed for ligand internalization than that offered by existing PSMA tracers to make lesions visible on PET/CT scans. Hence, 89ZrPSMA-DFO might be of significant benefit to patients in whom the search for weak PSMA-positive lesions is challenging. Radiation exposure should be weighed against the potential benefitof metastasis-directed therapy or salvage radiotherapy, which weinitiated in 36% (5/14) of our patients based on their 89Zr-PSMA-DFO PET scans. | ||
588 | |a Dataset connected to CrossRef, Journals: juser.fz-juelich.de | ||
700 | 1 | |a Kobe, Carsten |0 P:(DE-HGF)0 |b 1 | |
700 | 1 | |a Vázquez, Sergio Muñoz |0 P:(DE-HGF)0 |b 2 | |
700 | 1 | |a Fischer, Thomas |0 P:(DE-HGF)0 |b 3 | |
700 | 1 | |a Endepols, Heike |0 P:(DE-Juel1)180330 |b 4 |u fzj | |
700 | 1 | |a Hohberg, Melanie |0 P:(DE-HGF)0 |b 5 | |
700 | 1 | |a Reifegerst, Manuel |0 P:(DE-HGF)0 |b 6 | |
700 | 1 | |a Neumaier, Bernd |0 P:(DE-Juel1)166419 |b 7 |u fzj | |
700 | 1 | |a Schomäcker, Klaus |0 P:(DE-HGF)0 |b 8 | |
700 | 1 | |a Drzezga, Alexander E. |0 P:(DE-Juel1)177611 |b 9 |u fzj | |
700 | 1 | |a Dietlein, Markus |0 P:(DE-HGF)0 |b 10 |e Corresponding author | |
773 | |a 10.2967/jnumed.121.262290 |g Vol. 63, no. 4, p. 573 - 583 |0 PERI:(DE-600)2040222-3 |n 4 |p 573 - 583 |t Journal of nuclear medicine |v 63 |y 2022 |x 0022-3123 | ||
856 | 4 | |u http://juser.fz-juelich.de/record/910154/files/jnumed.121.262290.full.pdf |y OpenAccess | |
909 | C | O | |o oai:juser.fz-juelich.de:910154 |p openaire |p open_access |p VDB |p driver |p dnbdelivery |
910 | 1 | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 4 |6 P:(DE-Juel1)180330 | |
910 | 1 | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 7 |6 P:(DE-Juel1)166419 | |
910 | 1 | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 9 |6 P:(DE-Juel1)177611 | |
913 | 1 | |a DE-HGF |b Key Technologies |l Natural, Artificial and Cognitive Information Processing |1 G:(DE-HGF)POF4-520 |0 G:(DE-HGF)POF4-525 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-500 |4 G:(DE-HGF)POF |v Decoding Brain Organization and Dysfunction |9 G:(DE-HGF)POF4-5253 |x 0 | |
914 | 1 | |y 2022 | |
915 | |a DBCoverage |0 StatID:(DE-HGF)1190 |2 StatID |b Biological Abstracts |d 2021-01-27 | ||
915 | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2021-01-27 | ||
915 | |a OpenAccess |0 StatID:(DE-HGF)0510 |2 StatID | ||
915 | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2021-01-27 | ||
915 | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b J NUCL MED : 2021 |d 2022-11-19 | ||
915 | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2022-11-19 | ||
915 | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2022-11-19 | ||
915 | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2022-11-19 | ||
915 | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2022-11-19 | ||
915 | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2022-11-19 | ||
915 | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |d 2022-11-19 | ||
915 | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |d 2022-11-19 | ||
915 | |a IF >= 10 |0 StatID:(DE-HGF)9910 |2 StatID |b J NUCL MED : 2021 |d 2022-11-19 | ||
980 | |a journal | ||
980 | |a VDB | ||
980 | |a UNRESTRICTED | ||
980 | |a I:(DE-Juel1)INM-5-20090406 | ||
980 | |a I:(DE-Juel1)INM-2-20090406 | ||
980 | 1 | |a FullTexts | |
536 | |a Neuroimaging |0 G:(DE-HGF)POF4-5253 |c POF4-525 |f POF IV |x 0 | ||
336 | |a ARTICLE |2 BibTeX | ||
336 | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1668668583_5418 |2 PUB:(DE-HGF) | ||
336 | |a Output Types/Journal article |2 DataCite | ||
336 | |a article |2 DRIVER | ||
336 | |a Nanopartikel unedler Metalle (Mg0, Al0, Gd0, Sm0) |0 0 |2 EndNote | ||
336 | |a JOURNAL_ARTICLE |2 ORCID | ||
920 | |l yes | ||
920 | |k Molekulare Organisation des Gehirns; INM-2 |0 I:(DE-Juel1)INM-2-20090406 |l Molekulare Organisation des Gehirns |x 1 | ||
920 | |k Nuklearchemie; INM-5 |0 I:(DE-Juel1)INM-5-20090406 |l Nuklearchemie |x 0 | ||
991 | |a Drzezga, Alexander |0 P:(DE-Juel1)177611 |b 9 |u fzj | ||
991 | |a Schomäcker, Klaus |0 P:(DE-HGF)0 |b 8 | ||
991 | |a Neumaier, Bernd |0 P:(DE-Juel1)166419 |b 7 |u fzj | ||
991 | |a Reifegerst, Manuel |0 P:(DE-HGF)0 |b 6 | ||
990 | |a Dietlein, Felix |0 P:(DE-HGF)0 |b 0 | ||
991 | |a Hohberg, Melanie |0 P:(DE-HGF)0 |b 5 | ||
991 | |a Dietlein, Markus |0 P:(DE-HGF)0 |b 10 |e Corresponding author | ||
991 | |a Endepols, Heike |0 P:(DE-Juel1)180330 |b 4 |u fzj | ||
991 | |a Fischer, Thomas |0 P:(DE-HGF)0 |b 3 | ||
991 | |a Vázquez, Sergio Muñoz |0 P:(DE-HGF)0 |b 2 | ||
991 | |a Kobe, Carsten |0 P:(DE-HGF)0 |b 1 |